Tiziana gains on FDA clearance to start Alzheimer's treatment study
15/08/2023 16:17
** Drug developer Tiziana Life Sciences' TLSA.O shares
rise ~34% to $0.80
** Company says U.S. FDA has cleared the application to
begin trials for intranasal drug foralumab, which is being
studied as a treatment for Alzheimer's disease
** Stock up 36% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study